MDM2 and acute myeloid leukemia: Recently, phase III MIRROS (MDM2 antagonist Idasanutlin in Relapsed or Refractory acute myeloid leukemia [AML] for Overall Survival) trial evaluated the efficacy and safety of the small-molecule MDM2 antagonist idasanutlin plus cytarabine in patients with relapsed/refractory AML and demonstrated that nutlin treatment has no effect on overall survival or complete remission rates [379].